Novartis Inks Up to $7.2 Billion Deal with Abogen for mRNA Autoimmune Drug

Novartis has entered into a major licensing agreement with China’s Abogen Biosciences for an experimental mRNA-based therapy targeting autoimmune diseases. The deal could be worth up to $7.2 billion and significantly expands Novartis's pipeline in both autoimmune treatments and RNA-based technologies.

Deal Details

Under the terms announced by Abogen, Novartis will make an upfront payment of $575 million. The total potential value of the agreement includes additional payments tied to specific development, regulatory, and commercial milestones.

In exchange, Novartis receives:

• Exclusive worldwide rights to Abogen's lead autoimmune drug candidate, ABO2203.
• Options covering other programs that utilize Abogen's RNA technology platform.

Abogen Biosciences is also eligible to receive royalties on future net sales if the drug is successfully commercialized. The transaction is subject to customary closing conditions, including necessary regulatory approvals.

A Novel Therapeutic Approach

Ad

ABO2203 is designed to target and eliminate B cells, a type of immune cell implicated in many autoimmune diseases. The therapy uses messenger RNA (mRNA) to instruct the body's own cells to produce a molecule that helps T cells identify and destroy these problematic B cells.

According to Abogen, this mechanism represents a different approach to B cell depletion compared to existing treatments. The deal provides Novartis with a novel, clinical-stage asset that leverages the same mRNA technology well-known for its use in certain COVID-19 vaccines.

Strategic Significance

For Novartis, this agreement diversifies its drug pipeline by adding a promising experimental therapy in the high-value autoimmune space. It also grants the Swiss drugmaker access to Abogen’s broader RNA platform, signaling a strategic investment in the technology beyond vaccines.

Abogen Biosciences is a clinical-stage biotechnology company based in Suzhou, China, with a focus on oncology, autoimmune diseases, and vaccines. Its most advanced candidate is an mRNA-based shingles vaccine currently in Phase 3 trials in China, underscoring its experience in the field.